A 3-Part, Randomized, Multiple-Dose, Sequential Design Study of Bifeprunox in Healthy Subjects in Order to Establish a Titration Regimen With an Improved Tolerability Profile.
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2009
At a glance
- Drugs Bifeprunox (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Wyeth
- 15 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jan 2008 New trial record.